Comparison of the effect Of Metformin and Pioglitazone on hypertriglyceridemia(Dyslipidemia)

Comparison of the effect Of Metformin and Pioglitazone on hypertriglyceridemia

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230618058524N1

Enrollment

Registered

2023-07-05

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypertriglyceridemia. Condition 2: Metabolic syndrom. Pure hyperglyceridemia Metabolic syndrome

Interventions

Intervention 1: Intervention group: The group will be treated with metformin 1000 mg per day and will continue for three months, and at the end of the third month, re-evaluations will be done. Interve

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age : 25 - 70 ( male, female ) Triglyceride over than 150 mg/dl 25 < BMI < 40 Not using of Metformin, Pioglitazone Not using of Statin drugs

Exclusion criteria

Exclusion criteria: Underlying diseases such as Diabetes, Hypothyroidism, Heart diseases, Kidney failure, Liver failure, Severe infections, Cancer, Inflammatory diseases such as Rheumatoid arthritis and Inflammatory bowel disease. Drug side effects caused by Metformin and Pioglitazone Patients with familial hypertriglyceridemia Patients with Osteoporosis Pregnancy Breastfeeding Having diabetes Alcohol consumption, Addictive drugs BMI > 40 kg/m2 Dissatisfaction with participating or continuing to attend the study Patients with special diets Users of Statins and other Fat-lowering drugs, Corticosteroids

Design outcomes

Primary

Measure	Time frame
Triglyceride: It is one of the components of the lipid profile, which is one of the main diagnostic components and criteria in metabolic syndrome or insulin resistance syndrome, and has a direct relationship with the individual's insulin resistance conditions. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with mg/dl scale.;Cholesterol: including total cholesterol, LDL, HDL, which are other components of the body's lipid profile. It has an active participation in the structure of the body and their quantity and quality is a predictive factor for cardiovascular events. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with mg/dl scale.;Weight: Weight change is one of the results of treatment with some drugs. By measuring the weight in the study, results are also obtained regarding the effect of the drugs used on the weight of the patients. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Digital scales in the clinic.;Liver function test: Including AST and ALT, which are liver function tests; Any increase in the level of these variables requires liver examination. These enzymes can increase in different cases. They also increase in fatty liver disorder in the field of metabolic syndrome. Their normal level is mostly up to 35. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with U/L scale.	—

Measure

Time frame

Triglyceride: It is one of the components of the lipid profile, which is one of the main diagnostic components and criteria in metabolic syndrome or insulin resistance syndrome, and has a direct relationship with the individual's insulin resistance conditions. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with mg/dl scale.;Cholesterol: including total cholesterol, LDL, HDL, which are other components of the body's lipid profile. It has an active participation in the structure of the body and their quantity and quality is a predictive factor for cardiovascular events. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with mg/dl scale.;Weight: Weight change is one of the results of treatment with some drugs. By measuring the weight in the study, results are also obtained regarding the effect of the drugs used on the weight of the patients. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Digital scales in the clinic.;Liver function test: Including AST and ALT, which are liver function tests; Any increase in the level of these variables requires liver examination. These enzymes can increase in different cases. They also increase in fatty liver disorder in the field of metabolic syndrome. Their normal level is mostly up to 35. Timepoint: At the beginning of the intervention and then 3 months later. Method of measurement: Laboratory, Hitachi autoanalyzer with U/L scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Razavianzadeh

Islamic Azad University

Nasrin_Razavianzadeh50@gmail.com+98 23 3233 1876

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026